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Focal Nodular Hyperplasia:
Morphologic and Functional
Information from MR
Imaging with Gadobenate
Dimeglumine1
PURPOSE: To determine whether gadobenate dimeglumine (Gd-BOPTA) is able to
provide morphologic and functional information for characterization of focal nod-
ular hyperplasia (FNH).
MATERIALS AND METHODS: Sixty-three consecutive patients with proved FNH
were retrospectively examined. Magnetic resonance (MR) imaging with T2-
weighted turbo spin-echo and T1-weighted gradient-echo sequences was per-
formed. Images were acquired prior to and during the dynamic phase of contrast-
material enhancement and 1-3 hours after administration of 0.1 mmol/kg Gd-
BOPTA. Qualitative analysis of signal intensity and homogeneity on images in the
various phases of the MR study and examination for the presence of central scar or
atypical features were performed. On the basis of features observed in the precon-
trast and dynamic phases, lesions were defined as typical or atypical. Intensity and
enhancement patterns of the lesions and scars were also evaluated in the delayed
phase.
RESULTS: One hundred FNHs were depicted on MR images. Seventy-nine of 100
lesions demonstrated typical morphologic and enhancement characteristics. On
delayed phase images, 72% of 100 FNHs appeared hyperintense; 21%, isointense;
and 7%, slightly hypointense. The delayed pattern of enhancement was homoge-
neous, heterogeneous, and peripheral in 58%, 22%, and 20% of 100 FNHs,
respectively. Atypical morphologic features and lesion and/or scar enhancement
were observed in 21 of 100 FNHs. On delayed phase images, 76% of 100 atypical
FNHs appeared hyperintense, 14% isointense, and 10% slightly hypointense. Hy-
perintensity and isointensity allowed the correct characterization in 90% of atypical
FNHs.
CONCLUSION: Gd-BOPTA during both dynamic and delayed phases provides
morphologic and functional information for the characterization of FNH.
Focal nodular hyperplasia (FNH) is a benign tumorlike hepatic lesion that is the result of
a hyperplastic response to abnormal vasculature (1). Histologically, it is characterized by
the presence of normal hepatocytes with a malformed biliary system that leads to a
slowing of biliary excretion (2).
Sonographic features of FNH are nonspecific (3,4), whereas helical computed tomogra-
phy (CT) is able to provide sufficient information for the diagnosis of FNH only when the
lesion depicts typical features, such as a central scar and uniform hypervascularity (5).
Gadolinium contrast material–enhanced magnetic resonance (MR) imaging, in addition
to precontrast T1- and T2-weighted imaging, offers slightly improved sensitivity and
specificity for the diagnosis of FNH compared with CT (6–8). However, specific diagnosis
of FNHmay not be possible due to atypical CT and MR features, which have been reported
in 12%–83% of cases (2,3,9,10). When the diagnosis of FNH is not certain, radionuclide
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imaging or biopsy are often used, al-
though even these techniques do not al-
ways give a definitive diagnosis (11).
Contrast agents with hepato-specific
properties have been shown to increase
the sensitivity of MR imaging for the de-
tection of focal hepatic lesions (12–15),
although the role of these agents in the
characterization of focal lesions has yet
to be fully elucidated. Gadobenate dimeg-
lumine (Gd-BOPTA) (Multihance; Bracco
Imaging, Milan, Italy) is a paramagnetic
gadolinium-based contrast agent that, in
common with other gadolinium agents,
has a vascular-interstitial distribution in
the first fewminutes after injection. There-
after, some 2%–4% of the administered
dose is taken up by functioning hepato-
cytes and is excreted in the bile, while the
remaining dose undergoes renal elimina-
tion in amanner similar to that of conven-
tional gadolinium-based agents (16). The
fraction taken up by the hepatocytes
brings about a marked hyperintensity of
the liver that persists for at least 120 min-
utes after the injection (17). The usefulness
of Gd-BOPTA during the dynamic phase of
contrast agent distribution has recently
been reported (13,18,19). As yet however,
little has been documented on the poten-
tial of delayed MR imaging with Gd-
BOPTA for the characterization of focal le-
sions.
The purpose of this study was to de-
scribe the morphologic and functional
characteristics of FNH after Gd-BOPTA
administration.
MATERIALS AND METHODS
Study Population
Of 230 patients examined by using Gd-
BOPTA–enhanced MR imaging for a
known or suspected focal liver lesion, 63
patients were ultimately proved to have
at least one FNH lesion. These 63 patients
(51 women, 12 men; mean age, 36.8
years 6 10.8 [mean 6 SD]; range, 7–60
years) were examined between February
1999 and October 2000 at two institu-
tions. Of these patients, 29 presented
with symptoms and clinical signs such as
pain in the upper abdomen. The remain-
ing 34 patients were asymptomatic; for
these patients the presence of FNH was
an incidental finding at abdominal imag-
ing performed for other reasons. Twenty-
five women had a history of oral contra-
ceptive use for an average of 5.8 years 6
4.5; none of the men were using steroids.
Two patients had a history of a kidney
tumor, and one patient had clinical evi-
dence of chronic hepatitis.
A total of 100 lesions were detected in
the 63 patients included in the study.
These lesions were characterized as FNHs
at surgery (10 lesions in eight patients;
two lobectomies, two bisegmentecto-
mies, three segmentectomies, and one re-
section of pedunculated FNH), percuta-
neous biopsy (45 lesions in 37 patients),
other diagnostic imaging procedure (tech-
netium 99m diethyl-iminodiacetic acid
nuclear medicine scan, helical CT, MR),
and follow-up (45 lesions in 18 patients)
for a minimum of 2 years.
MR Imaging Protocol
The same MR imaging protocol was
used at both institutions. All patients un-
derwent MR imaging with a supercon-
ducting imager (Symphony, Magnetom
SP; Siemens, Erlangen, Germany) operat-
ing at 1.5 T. For 36 (57.1%) of 63 patients,
a phased-array torso multicoil was used.
For the remaining 27 (42.9%) patients a
whole-body coil was used. MR imaging
was performed by using T2-weighted
turbo spin-echo sequences (4,000/108
[repetition time msec/echo time msec])
and T1-weighted gradient-echo (GRE) se-
quences (110–140/4; flip angle, 80°). Im-
ages were acquired prior to the adminis-
tration of contrast agent in T2-weighted
spin-echo and T1-weighted GRE imag-
ing, during the dynamic phase of con-
trast enhancement following an intrave-
nously administered bolus of 0.1 mmol
Gd-BOPTA per kilogram of body weight.
T1-weighted GRE images were acquired
at 25–30 seconds (arterial phase), 70–90
seconds (portal venous phase), 3–5 min-
utes (equilibrium phase), and in a de-
layed phase following the administration
of Gd-BOPTA (T1-weighted GRE images
acquired at 1, 2, and 3 hours after the
injection). In 15 patients (18 lesions), T1-
weighted fat saturation GRE images in
addition to conventional GRE images
were acquired 3 hours after contrast
agent injection. Acquisition of images at
points as long as 3 hours after contrast
agent injection was performed because
the abnormal biliary excretion known to
occur in FNH might theoretically result
in a delayed elimination of Gd-BOPTA
relative to that occurring from the adja-
cent parenchyma. The section thickness
varied between 6 and 10 mm depending
on the hepatic volume. The entire liver
was imaged by using a single acquisition
during a single breath hold. The study
protocol was approved by the institu-
tional review board, and written in-
formed consent was obtained from every
patient.
Image Analysis
All images from both institutions were
evaluated independently by two radiolo-
gists (L.G., G.M.) with roughly equal ex-
perience (reader 1, 12 years; reader 2, 10
years). Qualitative analysis consisted of
an assessment of the signal intensity and
homogeneity on the image in the various
phases of the MR study (before, during,
and after Gd-BOPTA administration) and
a determination of whether a central scar
or atypical features were present. A con-
sensus evaluation on the part of the two
reviewers was performed for those images
for which reader disagreements were
present. Signal intensity was considered
homogeneous when equal intensity was
observed in all parts of the lesion with
the exception of the central scar, when
present.
On the basis of features observed in the
precontrast and dynamic phases and of
prior reports on the appearance and en-
hancement characteristics of FNH (5), the
lesions were defined as either typical or
atypical. They were also classified as small
(#3-cm diameter) or large (.3-cm diame-
ter). Lesions were considered typical when
they appeared as homogeneously isoin-
tense or slightly hyperintense on T2-
weighted images and isointense or slightly
hypointense on T1-weighted images be-
fore contrast material administration. Typ-
ical behavior during the dynamic phase of
contrast enhancement was noted when
the lesion demonstrated marked and ho-
mogeneous signal intensity enhancement
during the arterial phase, rapid and homo-
geneous signal intensity washout during
the portal venous phase, and signal isoin-
tensity (with the exception of the scar) dur-
ing the equilibrium phase.
A typical scar was revealed as a hy-
perintense central stellate area on T2-
weighted images and as a hypointense
area on T1-weighted images. During the
dynamic phase of contrast enhancement,
a typical scar appeared as hypointense
during the arterial and portal venous
phases and slightly hyperintense during
the equilibrium phase. The presence of a
scar was considered necessary for the def-
inition of a typical lesion only for lesions
greater than 3 cm.
Finally, the enhancement of the le-
sions and scars was evaluated in the de-
layed phase at 1, 2, and 3 hours after
contrast agent injection. Evaluation in
this phase was performed on the basis of
signal intensity and pattern of enhance-
ment.
Atypical features of lesions consisted of
the following: lesion heterogeneity, hy-
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pointensity in the portal or equilibrium
phases, the absence of a central scar in le-
sions greater than 3 cm, scar hypointensity
on T2-weighted images, and scar hypoin-
tensity in the equilibrium phase following
injection of contrast agent. Other atypical
features included the presence of a pseudo-
capsule, which was observed as a complete
hyperintense peri-lesional ring during the
equilibrium phase, the presence of hemor-
rhage, and the presence of necrosis.
RESULTS
A total of 100 lesions between 0.6 and
10.0 cm (4.0 cm 6 2.2) in diameter were
identified in 63 patients; 49 of 100 le-
sions were less than or equal to 3 cm in
diameter; and 51 were larger than 3 cm in
diameter. One lesion only was identified
in 48 (76.2%) of 63 patients while multi-
ple lesions (two to eight lesions) were
identified in 15 (23.8%) of 63 patients.
Lesions and Enhancement
The MR imaging appearance and be-
havior of the lesions in the various
phases are summarized in Table 1.
Precontrast phase.–A total of 17 (17%) of
100 FNHs on T2-weighted images and 18
(18%) of 100 FNHs on T1-weighted images
were not identifiable either because of in-
herent isointensity with the surrounding
normal parenchyma or because of the
small size of the lesion (diameter, 2.3 cm6
1.3; maximum, 5.5 cm; minimum, 0.6
cm). The signal intensity of the lesion was
homogeneous in 82 (99%) of 83 lesions
visible on T2-weighted images and in 81
(99%) of 82 lesions visible on precontrast
T1-weighted images (Fig 1a, 1b). Heteroge-
neous signal intensity was noted for one
lesion (9.0 cm in diameter) both on T2-
and T1-weighted images. This was due to
the presence of cystic areas with a fluid-
fluid layer consistent with previous hemor-
rhage.
Postcontrast dynamic phase.—Hyperin-
tensity was noted for all the lesions during
the arterial phase, with the degree of en-
hancement varying from moderate to
strong. A progressive reduction of signal
intensity enhancement over time leading
to isointensity in the portal venous and
equilibrium phases (Fig 1c, 1d) (Table 2)
was noted. In 99 of 100 lesions arterial
phase enhancement was homogeneous
(Fig 2a), while in one of 100 lesions it was
heterogeneous. In the portal venous and
equilibrium phases one lesion was hypoin-
tense and four lesions had a pseudocapsule
(Fig 2b).
Postcontrast delayed phase.—Of 100 le-
sions, signal intensity was greater than that
of the surrounding parenchyma for 67, 69,
and 72 lesions at 1, 2, and 3 hours, respec-
tively (Table 2). Generally, a greater signal
intensity compared with that of the sur-
rounding parenchyma was noted in the
later (3 hours) images than in the images
acquired at 1 and 2 hours after contrast
agent injection. Signal intensity was isoin-
tense to the surrounding parenchyma in
25, 23, and 21 of 100 lesions at 1, 2, and 3
hours after contrast agent injection, respec-
tively. Finally, slight hypointensity with
respect to the surrounding parenchyma
was noted for eight, eight, and seven of
100 lesions at 1, 2, and 3 hours after con-
trast agent injection, respectively. All le-
sions, including the hypointense ones,
showed enhancement after Gd-BOPTA in-
jection; for the hypointense lesions, the
enhancement was slightly lower than that
of the surrounding parenchyma. At 3
hours after contrast agent injection, the
following three main patterns of enhance-
ment were noted: homogeneous enhance-
ment in 52 (56%) of 93 lesions (Figs 1e, 1f,
2c), heterogeneous enhancement in 24
(26%) of 93 lesions (Fig 3), and peripheral
enhancement in 17 (18%) of 93 lesions (Fig
4b). For the seven hypointense lesions, ho-
mogeneous hypointensity was noted for
three (43%) lesions, heterogeneous hy-
pointensity was noted for two (28.5%)
lesions, while in two (28.5%) lesions a
central hypointensity with a peripheral
isointensity was noted.
Scar
The behavior of the scar in the various
phases of the examination is summarized
in Table 2.
Precontrast.—On T2-weighted images a
scar was visible in 25 (25%) of 100 le-
sions; in 24 FNHs the scar was hyperin-
tense, and in the other, it was hypoin-
tense. On T1-weighted images, a scar was
visible in 36 of 100 FNHs in each instance
as a hypointense area.
Postcontrast dynamic phase.—In the ar-
terial phase, a scar was recognizable in 43
of 100 FNHs as a hypointense area. In the
portal venous phase 28 scars remained
hypointense, while 10 became isoin-
tense, and four became hyperintense. Fi-
nally, in the equilibrium phase, six scars
appeared slightly hypointense, five isoin-
tense, and 35 hyperintense (Fig 1d).
Postcontrast delayed phase.—In the de-
layed phase, the visualization of the scars
was improved; a central scar was noted in
53 of 100 FNHs overall. At 1 hour after
contrast agent administration 50 of these
53 scars appeared hypointense while, at 2
and 3 hours after contrast agent adminis-
tration all 53 scars appeared hypointense
(Fig 1e). In 11 (22%) of 51 lesions, with a
diameter greater than 3 cm, a scar was not
recognizable in any phase of the examina-
tion. In the 49 lesions equal to or smaller
than 3 cm in diameter; no scar was de-
picted on precontrast images in 44 (90%)
lesions. On precontrast and postcontrast
dynamic phase images combined, a scar
was observed in seven of 49 (14%) lesions,
while on postcontrast delayed phase im-
ages (1–3 hours after contrast agent injec-
tion) a scar was noted in 15 (31%) of 49
lesions (Fig 4).
Typical FNH
Precontrast and postcontrast dynamic
phases.—A total of 79 (79%) of 100 lesions
demonstrated typical morphologic and en-
hancement characteristics. Among 49 le-
sions (#3 cm in diameter), 42 (80%) did
not depict a central scar. Because small
FNHs often lack a visible central scar, we
did not classify these as atypical.
Delayed phase.—Of 79 FNHs on 3-hour
TABLE 1
Morphologic Characteristics and Enhancement Pattern of 100 FNHs
on MR Images
Signal Intensity*
Precontrast Phase Dynamic Phase T1-weighted Delayed Phase
T1-weighted
T2-
weighted
T1-
weighted Arterial
Portal
Venous Equilibrium 1 Hour 2 Hour 3 Hour
Hyperintense 50 0 100 50 30 67 69 72
Isointense 33 20 0 49 69 25 23 21
Hypointense 0 62 0 1 1 8 8 7
Not visible 17 18 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100
Note.—Data are the number of lesions.
* Signal intensity of the FNH relative to that of the liver.
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postcontrast images, 56 (71%) appeared
hyperintense, 18 (23%) appeared isoin-
tense and five (6%) appeared slightly hy-
pointense. The delayed enhancement
pattern of 74 FNHs was homogeneous in
46 (62%), heterogeneous in 12 (16%),
and peripheral in 16 (22%).
Atypical FNH
Precontrast and postcontrast dynamic
phases.—In 21 (21%) of 100 FNHs atypi-
cal features associated with morphologic
characteristics, lesion enhancement, or
central scar enhancement were observed.
These features made characterization of
the lesions more difficult (Table 3). In
one lesion the signal intensity was lower
than that of the surrounding paren-
chyma in the equilibrium phase. In 11
(22%) of 51 FNHs greater than 3 cm in
diameter, a central scar was not observed.
In one lesion, a central scar appeared hy-
pointense on precontrast T2-weighted
images. Similarly, a hypointense scar was
noted in the postcontrast equilibrium
phase in six lesions. In four lesions, a
pseudocapsule was observed; in three of
these lesions, no central scar was present.
Finally, one lesion was heterogeneous
due to a previous hemorrhage.
Delayed phase.—Of 21 atypical FNHs
on 3-hour postcontrast images, 16 (76%)
appeared hyperintense, three (14%) be-
came isointense, and two (10%) appeared
slightly hypointense. The enhancement
pattern was homogeneous in nine (47%)
Figure 1. Chronic right upper abdominal pain in a 31-year-old woman. (a) Transverse turbo spin-echo T2-weighted (4,000/102) MR image shows
a large and homogeneous slightly hyperintense lesion (arrows) in the right lobe of the liver. Central stellate scar (curved arrow) is hyperintense.
(b–e) Transverse GRE T1-weighted (110/4; flip angle, 80°) MR images. (b) Precontrast image of the lesion is homogeneously isointense to the
surrounding liver parenchyma; central scar (curved arrow) is hypointense. (c) Arterial phase image obtained 25 seconds after administration of
Gd-BOPTA. Lesion is hyperintense and homogeneous; central scar is hypointense. (d) Equilibrium phase image obtained 5 minutes after
administration of Gd-BOPTA. Lesion is slightly hyperintense to adjacent liver parenchyma; central scar is hyperintense. (Fig 1 continues.)
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of the 19 isointense and hyperintense
nodules, heterogeneous in seven (37%),
and peripheral in three (16%).
Reader Disagreements
Reader disagreement with regard to
signal intensity in the delayed phase
(isointensity vs slight hyperintensity) oc-
curred in three instances. After a consen-
sus evaluation, two lesions were consid-
ered to be slightly hyperintense and one
lesion to be isointense to the surround-
ing parenchyma. Disagreement also oc-
curred in two instances with regards to
atypical findings. In one instance, there
was disagreement as to whether lesion
hypointensity in the equilibrium phase
should be considered typical or atypical;
consensus judged it to be atypical (pa-
tient 1, Table 3). In the other instance, a
small scar that was hypointense on T2-
weighted images was recognized as atyp-
ical by consensus (patient 18, Table 3).
DISCUSSION
FNH is the second most common lesion of
the liver after hemangioma. It is present in
3%–5% of the population and is more
common in women of childbearing age
(20).
Sonography is often used for the depic-
tion of FNH, despite the fact that this
technique does not provide specific and
confident characterization of lesions in
most patients. Helical CT with arterial and
portal venous phase imaging offers con-
fident depiction of FNH in many cases,
but atypical features may make specific
diagnosis difficult (2,3,9,10). Radionu-
clide imaging with sulfur colloid is gen-
erally considered useful in the character-
ization of FNH due to the uptake of tracer
by the Kupffer cells. However, uptake is
seen in only approximately two-thirds of
lesions (2) and is limited to the detection
only of large lesions.
The use of contrast-enhanced dynamic
phase MR imaging, with traditional extra-
cellularly distributed gadolinium-based
contrast agents, provides the greatest diag-
nostic sensitivity among the techniques in
current use, particularly when combined
with the information available on precon-
trast T1- and T2-weighted images (6). Nev-
ertheless, the presence of atypical features
does not permit accurate characterization
of FNH in every case, and current diagnosis
at MR imaging relies on the same morpho-
logic and hemodynamic features as helical
CT.
The availability of novel liver-specific
MR contrast agents increases the poten-
tial for accurate lesion characterization
(21,22). Gd-BOPTA is a paramagnetic
gadolinium-based contrast agent that be-
haves in a manner analogous to that of
other gadolinium-based agents during
the vascular-interstitial phase, in the first
minutes after injection, and as an agent
with liver-specific properties in a later de-
layed phase (16,17). Gd-BOPTA possesses
increased in vivo relaxivity compared
TABLE 2
Morphologic Characteristics and Enhancement Pattern of the Central Scar
on MR Images
Signal Intensity*
Precontrast Phase Dynamic Phase T1-weighted Delayed Phase
T1-weighted
T2-
weighted
T1-
weighted Arterial
Portal
Venous Equilibrium 1 Hour 2 Hour 3 Hour
Hyperintense 24 0 0 4 35 0 0 0
Isointense 0 0 0 10 5 3 0 0
Hypointense 1 36 43 28 6 50 53 53
Not visible 75 64 57 58 54 47 47 47
Total 100 100 100 100 100 100 100 100
Note.—Data are the number of central scars out of 100 FNHs.
* Signal intensity of the scar relative to that of the lesion.
Figure 1. (continued). (e) Image obtained 3 hours after administration of Gd-BOPTA. Nodule appears homogeneously hyperintense; scar is hypointense.
(f) Cut surface of pathologic specimen demonstrates homogeneous tissue component of the lesion and large stellate fibrous central scar (arrow).
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with other gadolinium-based agents,
and, unlike purely liver-specific agents,
this agent can be administered as a rapid
intravenous bolus to study the early dis-
tribution in the liver (17,23,24). The
amount of Gd-BOPTA uptake into the
hepatocytes (2%–4%) and the increased
relaxivity of the molecule leads to a
marked increase in liver parenchymal sig-
nal intensity (17), which has previously
been shown to facilitate the improved de-
tection of hepatic metastases (12,13,16,
19,25). Recently, delayed phase imaging
with Gd-BOPTA has been shown to be of
benefit for the characterization of hepato-
cellular carcinoma (26).
FNH is a benign lesion of hepatocellu-
lar origin which can provide an impor-
tant test for such a contrast agent; the
cellular structure of FNH is similar to that
of normal hepatic parenchyma apart
from the presence of an abnormal biliary
system. The use of radionuclide imaging
with tracers that simulate the behavior of
bilirubin, such as 99mTc diethyl-iminodi-
acetic acid, may reveal the uptake and
delayed excretion in FNH as a “hot spot”
(2). However, the use of Gd-BOPTA per-
mits both morphologic and functional
information to be obtained, with the ad-
vantage of greater spatial resolution than
that achievable with nuclear scintigra-
phy.
In the present study, 72 of 100 lesions
were hyperintense in the delayed phase
after injection of Gd-BOPTA. This can be
considered analogous to the “hot spots”
observed at scintigraphy. A further 21 le-
sions were isointense, while only seven
of 100 lesions were slightly hypointense.
The hyperintensity of the lesions permit-
ted the correct characterization of 19 of
21 FNHs that, on precontrast and post-
contrast dynamic phase images, pre-
sented sufficiently atypical morphologic
features as to prevent a definitive diagno-
sis.
For FNHs that have atypical features at
MR imaging or other imaging tests and
for small lesions (#3 cm), Gd-BOPTA–
enhanced MR with delayed imaging pro-
vides valuable information. In our series,
21 of 100 FNHs were considered to have
Figure 2. MR images in a 27-year-old asymptomatic woman. Transverse
GRE T1-weighted (120/4; flip angle, 80°) MR images. (a) Arterial phase
image obtained 25 seconds after administration of Gd-BOPTA. The nod-
ule (arrows) located in lateral segment of the liver shows homogeneous
and intense enhancement. No central scar is evident. (b) Equilibrium
phase image obtained 5 minutes after administration of Gd-BOPTA. Nod-
ule appears slightly hyperintense and delimited by a thin hyperintense
rim (arrows). (c) Image obtained 3 hours after administration of Gd-
BOPTA. Nodule is slightly and homogeneously hyperintense.
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atypical morphologic or lesion enhance-
ment, making the diagnosis of FNHmore
difficult. Among these 21 instances, de-
layed enhanced images (3 hours) showed
hyperintense (76%) or isointense (14%)
enhancement of the FNH, which permit-
ted a confident diagnosis.
The majority of small (#3-cm) FNHs
(42 [86%] of 49), did not have a visible
scar on precontrast or dynamic enhanced
images. Other investigators (2,3,5,9,10)
have reported similar findings onMR and
CT images. While the absence of a scar in
small FNHs cannot be considered atypi-
cal, it does make it more difficult to dis-
tinguish FNH from other hypervascular
neoplasms. Again, delayed phase imaging
proved useful; all 49 small FNHs showed
either hyperintense (33 [67%] lesions) or
isointense (16 [33%] lesions) enhance-
ment. In addition, a central scar was de-
tected on delayed images in 15 (31%) of
the 49 lesions compared with only seven
(14%) of 49 on dynamic phase images.
Considering all 100 FNHs, delayed
phase MR imaging permitted confident
diagnosis of 93 FNHs. On T1-weighted
images, the central scar appeared hypoin-
tense with precontrast and dynamic and
delayed enhanced MR imaging. This re-
flects the biologic distribution of the Gd-
BOPTA molecule, which accumulates se-
lectively in hepatocytes. In FNH, there is
prolonged and excessive hepatocellular
accumulation of the contrast agent be-
cause FNH lacks a well-formed bile cana-
licular system to permit normal excretion
(2,5).
Whether Gd-BOPTA–enhanced MR im-
aging will facilitate distinction of FNH
from other neoplasms of hepatocellular or-
igin is an important but unresolved ques-
tion. A principal limitation of the present
study is the absence of a blinded compari-
son with other hypervascular lesions.
Work is ongoing to determine the sensitiv-
ity and specificity of delayed enhancement
for the differential diagnosis of benign and
malignant hypervascular liver lesions. The
accumulation of the agent in hepatocellu-
lar carcinoma has been shown to correlate
with the residual hepatocytic function in
the neoplastic cells, as judged by the pres-
ence of bile in the neoplasm. In a prior
report (26), only one of 34 hepatocellular
carcinoma lesions demonstrated hyperin-
tensity on delayed images following Gd-
BOPTA. We are unaware of any specific
study of the appearance of hepatocellular
adenoma with Gd-BOPTA–enhanced MR.
Our anecdotal experience with four cases
of adenoma and one of adenomatosis (un-
published data) demonstrated much less
intense enhancement of the adenoma on
dynamic phase MR images and a markedly
hypointense appearance on delayed im-
ages relative to FNH or normal liver. Al-
though adenomas have functioning hepa-
tocytes, they lack bile ducts. It is therefore
likely that bilirubin metabolism is blocked
in the adenoma, as confirmed by absence
of bile in resected adenomas (27). Altered
hepatocellular metabolismmay inhibit the
uptake of Gd-BOPTA in the adenoma
thereby accounting for its hypointense ap-
pearance on delayed MR images. We also
have anecdotal experience with three cases
of fibrolamellar hepatocellular carcinoma;
none of these tumors showed delayed en-
TABLE 3
Atypical Findings in FNHs on MR Images
Patient No. Atypical Findings
Enhancement Pattern of Lesions
on Delayed Phase Images
1 Hour 2 Hour 3 Hour
1 Hypo in equilibrium phase Iso Iso Iso
2 Hemorrhage and calcifications Iso Iso Hyper
3 Pseudocapsule Hyper Hyper Hyper
4 No scar Hyper Hyper Hyper
5 No scar Hyper Hyper Hyper
6 No scar Iso Iso Iso
7 No scar Hyper Hyper Hyper
8 No scar Hyper Hyper Hyper
9 No scar Hyper Hyper Hyper
10 No scar Hyper Hyper Hyper
11 No scar; pseudocapsule Iso Iso Iso
12 No scar; pseudocapsule Hyper Hyper Hyper
13 Scar hypo in equilibrium phase Hyper Hyper Hyper
14 Scar hypo in equilibrium phase Hyper Hyper Hyper
15 Scar hypo in equilibrium phase Hyper Hyper Hyper
16 Scar hypo in equilibrium phase Hyper Hyper Hyper
17 Scar hypo in equilibrium phase Hyper Hyper Hyper
18 Scar hypo in T2-weighted phase Hypo Iso Hyper
19 Scar hypo in equilibrium phase Hyper Hyper Hyper
20 No scar; pseudocapsule Hypo Hypo Hypo
21 No scar Hypo Hypo Hypo
Note.—Hyper 5 hyperintense, Iso 5 isointense, Hypo 5 hypointense.
Figure 3. Transverse GRE T1-weighted (107/4.8; flip angle, 80°) fat-
suppression MR image obtained in a 36-year-old man with intermit-
tent right flank pain 3 hours after administration of Gd-BOPTA. Large
partially exophytic mass (arrows) located in the right lobe of the liver
shows heterogeneous hyperintensity.
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hancement on Gd-BOPTA-enhanced MR
images.
Other liver-specific MR contrast agents
are available. Manganese diproxyl diphos-
phate (mangafodipir trisodium Teslascan;
Nycomed-Amersham, Princeton, NJ) is a
recently developed hepatobiliary MR con-
trast agent that improves the detection of
liver metastases due to selective enhance-
ment of functioning hepatocytes. Potential
disadvantages of mangafodipir include its
uptake and enhancement by some benign
and malignant (hepatocellular carcinoma)
hepatic neoplasms, limiting its ability to
characterize some hepatic lesions (21,28).
Superparamagnetic iron oxides (SPIO)
(Feridex; Advanced Magnetics, Prince-
ton, NJ and Endorem; Laboratoire Guer-
bet, Roissy, France) are superparamag-
netic liver-specific contrast agents. When
intravenously administered, they are ex-
tracted from the intravascular space by
the reticulo-endothelial system and de-
posited mainly in the Kupffer cells. En-
hancement by using SPIO alters the sig-
nal intensity of normal liver, but not the
signal intensity of neoplasms, which lack
Kupffer cells, and should increase depic-
tion of liver metastases (14).
Kupffer cells are usually observed in
FNH, and, along with malformed biliary
ducts, are a major histologic feature of
this lesion. Uptake of SPIO by FNH is
therefore common (22). However, some
lesions that lack Kupffer cells, including
hemangioma and adenoma, have been
reported (29) to demonstrate uptake of
SPIO also. This appears to be due to pool-
ing of the contrast agent in the vascular
pools and peliosis-like dilatated vessels
that characterize hemangiomas and ade-
nomas, respectively (29).
It is important to note that neither
mangafodipir nor SPIO have been docu-
mented to be safe and effective as a bolus
contrast agent injection, making them
ineffective for demonstration of the vas-
cular and interstitial phases of liver lesion
enhancement.
Further work might be usefully di-
rected toward comparing the imaging
features of FNH after Gd-BOPTA admin-
istration with those observed after ad-
ministration of SPIO or mangafodipir.
Similarly, a direct comparison of Gd-
BOPTA–enhanced MR imaging of FNH
with other imaging techniques, such as
nuclear scintigraphy, is warranted.
In summary, Gd-BOPTA is a useful
contrast agent for the study of FNH, of-
fering opportunities during both the dy-
namic and delayed phases of contrast en-
hancement to acquire morphologic and
functional information for the character-
ization of these lesions. Our experience
suggests that the MR protocol should in-
clude T2-weighted turbo spin-echo se-
quences and T1-weighted GRE images ac-
quired prior to and during the dynamic
phase of an intravenously administered
bolus of this agent. Delayed imaging (3
hours) provides important information
when the other MR sequences do not
reveal a specific diagnosis. MR imaging
with Gd-BOPTA should be considered
whenever FNH is suspected in a patient.
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